Literature DB >> 18752768

The role of natriuretic peptides in heart failure.

Daniel D Correa de Sa, Horng H Chen.   

Abstract

Heart failure is a clinical syndrome associated with progressive cardiac, vascular, and renal dysfunction. Regardless of the initial injury, investigations have demonstrated that neurohormones play an important role in the complex multiorgan and cellular adaptations. Natriuretic peptides play a key role in this process, antagonizing the actions of the renin-angiotensin-aldosterone system, thus promoting vasodilatation and natriuresis. Other important physiologic properties of the natriuretic peptides are prolusitropic, sympathoinhibitory, antiproliferative, anti-ischemic, anti-inflammatory, and antioxidative. Administering exogenous natriuretic peptide is a US Food and Drug Administration-approved therapy for patients with advanced decompensated congestive heart failure. Also, measuring natriuretic peptide levels has diagnostic and prognostic value. More studies are needed to define the full potential of this unique family of endogenous peptides.

Entities:  

Year:  2008        PMID: 18752768     DOI: 10.1007/s11897-008-0027-8

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  47 in total

1.  Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure.

Authors:  Adam M Hawkridge; Denise M Heublein; H Robert Bergen; Alessandro Cataliotti; John C Burnett; David C Muddiman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

2.  Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide.

Authors:  Denise M Heublein; Brenda K Huntley; Guido Boerrigter; Alessandro Cataliotti; Sharon M Sandberg; Margaret M Redfield; John C Burnett
Journal:  Hypertension       Date:  2007-03-19       Impact factor: 10.190

3.  Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice.

Authors:  Yong Wang; Monique C de Waard; Anja Sterner-Kock; Holger Stepan; Heinz-Peter Schultheiss; Dirk J Duncker; Thomas Walther
Journal:  Eur J Heart Fail       Date:  2007-04-03       Impact factor: 15.534

4.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

Authors:  W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

5.  AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure.

Authors:  Wei Wang; Ying Ou; Yanggu Shi
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

6.  Signaling pathways involved in atrial natriuretic factor and dopamine regulation of renal Na+, K+ -ATPase activity.

Authors:  Alicia H Correa; Marcelo R Choi; Mariela Gironacci; María S Valera; Belisario E Fernández
Journal:  Regul Pept       Date:  2006-09-26

7.  Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.

Authors:  Friedrich M Fruhwald; Astrid Fahrleitner-Pammer; Rudolf Berger; Francisco Leyva; Nick Freemantle; Erland Erdmann; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi; Jean-Claude Daubert; John G F Cleland
Journal:  Eur Heart J       Date:  2007-02-13       Impact factor: 29.983

8.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

Authors:  Masafumi Kitakaze; Masanori Asakura; Jiyoong Kim; Yasunori Shintani; Hiroshi Asanuma; Toshimitsu Hamasaki; Osamu Seguchi; Masafumi Myoishi; Tetsuo Minamino; Takahiro Ohara; Yoshiyuki Nagai; Shinsuke Nanto; Kouki Watanabe; Shigeru Fukuzawa; Atsushi Hirayama; Natsuki Nakamura; Kazuo Kimura; Kenshi Fujii; Masaharu Ishihara; Yoshihiko Saito; Hitonobu Tomoike; Soichiro Kitamura
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

9.  Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study.

Authors:  Margaret M Redfield; Richard J Rodeheffer; Steven J Jacobsen; Douglas W Mahoney; Kent R Bailey; John C Burnett
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

10.  The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.

Authors:  Maria Rosa Costanzo; R S Johannes; Michael Pine; Vikas Gupta; Mitchell Saltzberg; Joel Hay; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

View more
  2 in total

Review 1.  Natriuretic peptide testing in high-risk pregnancy: a preventive opportunity?

Authors:  Meera Kumari; W H Wilson Tang; Anjli P Maroo
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 2.  Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.

Authors:  Stuart B Prenner; Sanjiv J Shah; Clyde W Yancy
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.